Men's Health

Men using long-term, high-dose prescription opioids for back pain were about 50% more likely to be using medications for erectile dysfunction than men with back pain who were not using opioids, researchers reported.

Intensity-modulated radiation therapy may not be more effective than conformal radiation therapy in patients who have undergone radical prostatectomy, say researchers from the University of North Carolina, Chapel Hill.

Data from a third planned interim analysis of a phase III trial are consistent with earlier results supporting the efficacy and safety of abiraterone acetate (Zytiga) as a treatment for chemotherapy-naïve men with metastatic castration-resistant prostate cancer.

Three urologists discuss how they review prostate cancer treatment options with their patients.

The new-generation GreenLight XPS-180W laser system (American Medical Systems, Minnetonka, MN) achieved an improved rate of tissue vaporization and overall efficacy in patients with BPH compared to an earlier generation laser, according to results of a recent multicenter study.

Robot-assisted laparoscopic prostatectomy in patients with intermediate- or high-risk cancers achieves outcomes similar to those seen with the open procedure, say researchers from Vanderbilt University, Nashville, TN.

In this case, the woman claimed her damages from the negligent nerve injury included pain and weakness in her legs and a second operation to replace the sling.

The clinical advantages of adjuvant or salvage radiation therapy in patients treated for prostate cancer by radical prostatectomy is currently a much-debated issue and is frequently decided for the individual patient. New evidence, however, seems to indicate that secondary radiation therapy (RT) does not negatively affect urinary continence.

A new study has confirmed that a genetic test that measures cell cycle progression (CCP) can be a useful tool for predicting which patients will have prostate cancer recurrence, especially when combined with existing information from laboratory and pathology tests.

The FDA has approved radium Ra 223 dichloride (Xofigo) injection for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease.

Older prostate cancer patients with three or more underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer, according to a multicenter study led by UCLA urologists.

Saying it’s time to take the guesswork out of buying a legitimate drug online and combat counterfeiters, Pfizer has launched a prescription-fulfillment website for the phosphodiesterase type-5 inhibitor sildenafil citrate (Viagra).

The AUA and the American Society for Radiation Oncology (ASTRO) have released a joint guideline on radiation therapy after prostatectomy for patients with and without evidence of prostate cancer recurrence.

A new genomic test for prostate cancer appears to help predict whether men are more likely to harbor an aggressive form of the disease, report researchers from the University of California, San Francisco.

New evidence from the European Randomized Study of Screening for Prostate Cancer (ERSPC) suggests that prostate cancer screening is beneficial, particularly in the core age group of 55 to 69 years.

Men with symptomatic BPH had statistically significant, durable improvement in lower urinary tract symptoms (LUTS) following an office-based, minimally invasive prostatic urethral lift procedure, results of a pivotal randomized trial showed.

Wake Forest University researchers have conducted early, pre-clinical work that they say supports further research on the use of spermatogonial stem cell (SSC) transplantation as a potential treatment for male infertility.

Robot-assisted laparoscopic prostatectomy in patients with intermediate- or high-risk cancers achieves outcomes similar to those attained by the open procedure, results of a large retrospective comparative study indicate.

Following the rollout of several new treatments for metastatic, castration-resistant prostate cancer (mCRPC), a new AUA clinical guideline is aimed at assisting in clinical decision making.

Prostate cancer patients who also have long-term diabetes mellitus and/or diabetes with organ failure may have a higher likelihood of developing more aggressive, poorly differentiated disease, new study data suggest.

The most recent data from the COU-AA-302 phase III trial support the efficacy and safety of abiraterone acetate (Zytiga) as a treatment for metastatic castration-resistant prostate cancer in men who are chemotherapy-naive.

The AUA has released a PSA-focused, evidence-based guideline on early detection of prostate cancer that is intended to assist the urologist in advising an average-risk, asymptomatic man about prostate cancer screening, said H. Ballentine Carter, MD.

Drugs and devices in the pipeline from Medivation, Inc.; Astellas Pharma Inc.; TARIS Biomedical; Exelixis, Inc.; and Bioniche Life Sciences Inc.

A new closer look at genomes in prostate cancer has revealed that genetic mutations occur in abrupt, periodic bursts, causing complex, large-scale reshuffling of DNA driving the development of the disease.

Obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared with nonobese men and were at a greater risk for subsequently developing prostate cancer, a recently published study found.